A DOJ/DEA order moves FDA-approved cannabis products, which subsequently affects Nasdaq's new listing pathway.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• Nasdaq →

  American fully electronic stock exchange

  • Apple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Mon 17:22
  • Vanguard Short-Term Inflation-Protected Securities ETF is disclosing its holdings to the SEC and trading on the Nasdaq electronic stock exchange.Mon 16:28

Related events

• Above Food Ingredients is seeking relisting on Nasdaq and operates under US federal securities laws.Aug 18
• Alvotech utilized Nasdaq for its public stock listing and is currently undergoing comprehensive review by the FDA for biosimilar applications.Aug 19
• Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.Sep 22
• Agencies (FDA and DEA) implement a regulatory shift concerning cannabis.Sat 02:48
• Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.Aug 9